Major Depressive Disorder News and Research RSS Feed - Major Depressive Disorder News and Research

Emotion regulation distinguishes unipolar and bipolar depression

Emotion regulation distinguishes unipolar and bipolar depression

Patients with bipolar disorder regulate their emotions differently from those with major depressive disorder in both depressed and remitted states, a study shows. [More]
Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study. [More]
Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment. [More]
Clinical features identified to distinguish bipolar I disorder from MDD

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder. [More]
Neuronetics completes Series F Financing Round

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million. [More]
Tal Medical raises $14 million funding round from new and existing investors

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors. [More]
Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI). [More]
Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. [More]
Study finding suggests importance of individually-tailored treatment for depression

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression. [More]
Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

A recent study published in the March 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry finds that Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT). [More]
Pain from social rejection lasts longer for people with untreated depression

Pain from social rejection lasts longer for people with untreated depression

Rejected by a person you like? Just "shake it off" and move on, as music star Taylor Swift says. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Brain scans can predict therapeutic responses to talk therapy

Brain scans can predict therapeutic responses to talk therapy

UNC School of Medicine researchers have shown that brain scans can predict which patients with clinical depression are most likely to benefit from a specific kind of talk therapy. [More]

Chronic pain common in affective disorders

Patients with major depressive disorder or bipolar disorder frequently report chronic pain at multiple sites, research shows. [More]
Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Nearly three-quarters of homeless adults with mental illness in Canada show evidence of cognitive deficits, such as difficulties with problem solving, learning and memory, new research has found. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
Study highlights public health significance of depression among U.S. adolescents

Study highlights public health significance of depression among U.S. adolescents

A recent study published in the January 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry underscores the important public health significance of depression among U.S. adolescents. [More]
Advertisement
Advertisement